Sun Pharma receives USFDA nod for anti-cholesterol drug
Sun Pharma’s generic version of ezetimibe tablets—used to reduce high cholesterol levels—receive USFDA nod
Latest News »
- Market round-up: China’s growth looks like it has peaked for 2017
- Godrej Consumer Products eyeing acquisition to enter skincare market
- Myntra aims to launch loyalty programme
- Accenture raises the stakes with $1.8 billion acquisition plan
- Blackstone exits Jagran Prakashan holding firm, sells stake to promoters
New Delhi: Drug major Sun Pharmaceutical Industries’ wholly-owned subsidiary has received nod from the US health regulator for its generic version of ezetimibe tablets used to reduce high cholesterol levels.
One of the company’s wholly-owned subsidiaries has received final approval from the USFDA for its abbreviated new drug application (ANDA) for generic version of Zetia, ezetimibe tablets, Sun Pharma said in a BSE filing.
The approval is for the tablets in the strength of 10 mg. The tablets are generic versions of Merck’s Zetia, Sun Pharma said.
“As per IMS, ezetimibe tablets had annual sales of approximately $2.7 billion in the US for the 12 months ended April 2017,” it added.
The stock of Sun Pharmaceutical Industries was trading at Rs539.50 on the BSE, up 1.19%.